Hereditary and Sporadic Forms of Aβ-Cerebrovascular Amyloidosis and Relevant Transgenic Mouse Models by Kumar-Singh, Samir
Int. J. Mol. Sci. 2009, 10, 1872-1895; doi:10.3390/ijms10041872 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Review 
Hereditary and Sporadic Forms of Aβ-Cerebrovascular 
Amyloidosis and Relevant Transgenic Mouse Models 
Samir Kumar-Singh 
1,2,3 
1  Neurodegenerative Brain Diseases Group, VIB Department of Molecular Genetics, University of 
Antwerp, Antwerpen - CDE, Universiteitsplein 1, B-2610, Antwerpen, Belgium;  
E-Mail: samir.kumarsingh@molgen.vib-ua.be; Tel. +3232651002; Fax: +3232651012 
2  Laboratory of Neurogenetics, Institute Born Bunge, University of Antwerp, Antwerpen, Belgium 
3  University of Antwerp, Antwerpen, Belgium  
Received: 16 January 2009; in revised form: 14 April 2009 / Accepted: 20 April 2009 /  
Published: 23 April 2009 
 
Abstract: Cerebral amyloid angiopathy (CAA) refers to the specific deposition of amyloid 
fibrils in the leptomeningeal and cerebral blood vessel walls, often causing secondary 
vascular degenerative changes. Although many kinds of peptides are known to be 
deposited as vascular amyloid, amyloid-β (Aβ)-CAA is the most common type associated 
with normal aging, sporadic CAA, Alzheimer’s disease (AD) and Down’s syndrome. 
Moreover, Aβ-CAA is also associated with rare hereditary cerebrovascular amyloidosis 
due to mutations within the Aβ domain of the amyloid precursor protein (APP) such as 
Dutch and Flemish APP mutations. Genetics and clinicopathological studies on these 
familial diseases as well as sporadic conditions have already shown that CAA not only 
causes haemorrhagic and ischemic strokes, but also leads to progressive dementia. 
Transgenic mouse models based on familial AD mutations have also successfully 
reproduced many of the features found in human disease, providing us with important 
insights into the pathogenesis of CAA. Importantly, such studies have pointed out that 
specific vastopic Aβ variants or an unaltered Aβ42/Aβ40 ratio favor vascular Aβ 
deposition over parenchymal plaques, but higher than critical levels of Aβ40 are also 
observed to be anti-amyloidogenic. These data would be important in the development of 
therapies targeting amyloid in vessels. 
Keywords: Alzheimer’s disease; cerebrovascular amyloidosis; CAA; dense-core plaques; 
senile plaques; amyloid β protein; transgenic mice; pathogenesis; therapy. 
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1. Introduction 
Accumulation of amyloid β-protein (Aβ) in the cerebral vasculature is a common pathological 
feature of Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA) [1,2,3]. Many 
biochemically distinct types of amyloid have been reported to deposit in cerebral vessels such as Aβ, 
cystatin-C (Icelandic CAA), transthyretin, gelsolin, prion protein, and the ABri and ADan subunits in 
familial British and familial Danish dementia [3]. However, CAA caused by Aβ is the most common 
form of sporadic CAA and also occurs in AD patients [1,2,3]. 
Aβ is a 40 to 42 aminoacid peptide derived from the amyloid precursor protein (APP), a type 1 
transmembrane glycoprotein, through sequential proteolysis by β-secretase and γ-secretase/presenilin 
complex. A prior cleavage by α-secretase prevents the generation of full-length Aβ and generates p3 
(Figure 1). Aβ has a pronounced propensity to form fibrillar aggregates, and the longer, more 
hydrophobic Aβ42 is also more prone to form fibrils than the shorter Aβ40 isoform. According to the 
amyloid cascade hypothesis, Aβ deposition is causative for the pathogenesis of AD [4]. One of the 
most convincing evidence to support this premise is identification of mutations in APP near the β- or 
γ-secretase cleavage site or in the presenilin gene causing familial forms of AD that increase the 
absolute or relative levels of Aβ42 [4]. While in these familial forms Aβ is also deposited in vessels, 
the most severe CAA is observed in patients with APP mutations that lie within the Aβ domain such as 
Flemish, Dutch, Italian, Arctic, and Iowa, amongst others (Figure 1). 
2. Clinical and Pathological Consequences of CAA 
Aβ CAA (henceforth CAA) is shown to affect leptomeningeal and cortical arteries, arterioles, 
capillaries, venules and veins in both sporadic and familial CAA, and in almost all AD patients [5,6,1]. 
Depending on the predominant type of vessel involved, two types of CAA have been distinguished: 
CAA-type 1 and type 2. CAA-type 1 affects meningeal and cortical arterioles, capillaries, veins and 
venules while CAA-type 2, also called large-vessel CAA, affects meningeal and cortical vessels but 
has a tendency to spare cortical capillaries [7]. In CAA-type I, Aβ frequently permeates the 
glioadventitial junction of capillaries and small arterioles and extends into the parenchyma as 
"dyshoric angiopathy" [5,8]. Also, depending on the level of vascular involvement, a simple 3-tiered 
grading system of mild, moderate, and severe CAA has been proposed [9]. In “mild” CAA, focal Aβ 
deposition restricted to the tunica media occurs in an otherwise normal vessel. In “moderate” CAA, Aβ 
deposition involves the entire thickness of tunica media, thus completely replacing the smooth muscle 
cell layer. No evidence of recent or old blood leakage is found. In “severe” CAA, Aβ deposition 
involves other vascular wall layers and the vascular architecture is severely disrupted with secondary 
changes such as microaneurysmal dilatation, fibrinoid necrosis, and vessel rupture [9,10,11]. Int. J. Mol. Sci. 2009, 10  
 
 
1874
Figure 1. Schematic representation of amyloid precursor protein (APP), positions of the 
Aβ sequence, transmembrane domain of APP (Tm), and sites of α-, β- and γ-secretase 
cleavage.  
 
NH2 and COOH indicate the N-terminus and C-terminus of the protein. Aβ sequence is enlarged 
below. The constitutive proteolytic cleavage by α- and γ-secretases leads to the formation of the 
short p3 peptide and processing by β- and γ-secretases leads to Aβ40 and Aβ42 peptides with a 
consecutive release of a C-terminal APP intracytoplasmic domain (AICD). Also shown are 
AD/CAA-causing pathogenic amino acid substitutions within APP (see also Table 2 and visit 
www.molgen.ua.ac.be/ADMutations for a complete and updated list of these mutations). 
 
CAA also has important and sometimes fatal pathological consequences. One of the most well-
recognized complications of CAA is spontaneous, often recurrent, intracerebral haemorrhage, usually 
involving the cortex and/or subcortical white matter [12,13,14,9,15,16]. Secondly, CAA also increases 
the risk of cerebral infarction, especially in the watershed areas, and is frequently associated with 
ischaemic leucoencephalopathy [17,18,19]. Thirdly, CAA has also been associated with progressive 
dementia in sporadic CAA patients [20,21,22]. Even in patients devoid of any AD pathology, CAA has 
been significantly associated with the presence of clinical dementia [23,22]. Interestingly, CAA-type I 
has been shown to be more closely related to AD pathology than large-vessel CAA [1,24], and 
increased perivascular phosphorylated tau as well as perivascular inflammation is observed with this 
type of CAA (see later). 
3. APP Mutations within the Aβ Sequence Associated with Cerebrovascular Amyloidosis 
The genetics of CAA is tightly linked to that of AD. However, research conducted on CAA has 
been more rewarding in improving our understanding of the biochemistry and molecular genetics of 
Aβ amyloidogenesis. Not only was Aβ peptide identified first from amyloid deposited in vascular 
walls in AD and Down’s syndrome patients [25], but the APP mutations were also identified for the 
first time in a familial form of CAA called hereditary cerebral haemorrhage with amyloidosis – Dutch 
type (HCHWA-D). HCHWA-D is an autosomal dominant form of CAA characterized by recurrent 
haemorrhages due to extensive Aβ deposition in cerebral blood vessel walls and diffuse amyloid 
plaques but absence of dense-core senile plaques or neurofibrillary tau pathology [26,27,28] (Table 1). Int. J. Mol. Sci. 2009, 10  
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HCHWA-D patients were identified to carry Dutch APP mutation at codon 693 (APP 770 isoform) 
replacing a glutamate (E) by a glutamine (Q) [29,30]. 
 
Table 1. Extracellular cerebral amyloid deposits commonly present in familial and sporadic Aβ-
CAA and AD patients and transgenic mouse models. 
CAA 
Cerebral amyloid angiopathy; pathological changes occurring in cerebral blood 
vessels caused by deposition of amyloid protein of different origins, but here 
due to Aβ. 
Dense-core 
plaques 
Also referred to as "neuritic", "senile", "classic", or "mature" plaques. The 
central compact dense-core is surrounded by a corona of diffuse plaque. The 
corona contains predominantly Aβ42 and is ThS-negative. The core is ThS-
positive. Almost always associated with proximate phospho-tau pathology. 
Dense plaques 
ThS-positive compact amyloid without the corona of diffuse plaques. Major 
compact plaque type in transgenic mouse models. Biochemically resembles 
cores of the dense-core plaques. In this review, also sometimes used to include 
dense-core plaques. 
Diffuse 
plaques 
Loosely arranged fibrils that are usually ThS-negative. Best recognized with 
immunohistochemistry and are constituted predominantly of Aβ42. Are not 
commonly associated with proximate phospho-tau pathology. 
 
Soon after, the Flemish APP mutation replacing a glycine (G) by an alanine (A) at the adjacent 
codon 692 was identified in another Dutch family suffering from presenile dementia and cerebral 
haemorrhage inherited in an autosomal dominant pattern [31]. Interestingly, clinical phenotypes in 
Flemish APP carriers overlapped to the extent that cerebral haemorrhages were reported in offspring 
of patients having dementia while patients with strokes had offspring developing progressive dementia 
[32,33]. Flemish APP carriers were also shown to have definitive AD with numerous, large senile 
plaques accompanied by a very severe degree of leptomeningeal and parenchymal CAA [34,33,35]. 
Moreover, in contrast to HCHWA-D patients, Flemish APP carriers have neurofibrillary tau pathology 
[33,34] (Figure 2). 
Subsequently, other APP mutations within the Aβ sequence were also identified – such as "Italian" 
(E693K), "Arctic" (E693G), "Japanese" (E693Δ), "Iowa" (D694N) and L705V APP mutations (Table 
2; www.molgen.ua.ac.be/ADMutations). The pathology associated with these mutations resembled 
either Dutch or Flemish APP pathology by having a pure CAA/cerebral haemorrhage or a mixed AD – 
CAA/cerebral haemorrhage phenotype. For instance, Italian APP and APP L705V mutation resembles 
the Dutch APP carriers with a predominant CAA with or without recurrent haemorrhages [36,37]. 
Also, similar to Dutch APP mutation, neurofibrillary tangles (NFT) were absent in APP L705V 
carriers [37] or were mild and restricted to the archicortex as in the Italian APP carriers [36]. The 
Arctic and Iowa APP carriers resemble the Flemish APP carriers by having a mixed AD/ severe CAA 
phenotype, although haemorrhagic strokes are not observed [38,39,40,41]. Moreover, consistent to an 
AD phenotype, parenchymal, ringlike plaques are observed in the Arctic APP carriers [39]. In addition Int. J. Mol. Sci. 2009, 10  
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to these APP mutations near the α-secretase site, intragenic Aβ mutations are also reported near the β- 
and γ-secretase site of APP. For instance, APP A713T mutation near the γ-secretase site reportedly 
leads to progressive dementia and multiple strokes, and pathological studies confirm AD with severe 
CAA with multiple infarcts in brain [42]. Similarly, the APP A673V mutation near the β-secretase site 
of APP has been shown to be associated with AD type of dementia and, consistent with an autosomal 
recessive pattern of inheritance, is pathogenic only in a homozygous state [43]. Neuropathological data 
for APP A673V carriers is not yet available [43]. 
Figure 2. Spectrum of disease from primarily hereditary amyloidosis of Dutch and Flemish 
type to familial forms of Alzheimer’s disease (AD) and to mouse models of AD.  
 
The upper and middle panels depict Aβ staining with monoclonal antibody 4G8 in an HCHWA-D 
(E693Q) patient with CAA (a, e), a Flemish APP carrier with both CAA and senile plaques (b, f); a 
presenilin (PS)-1 L282V AD patient with senile plaques and prominent CAA (c, g), and Tg2576 
mouse model with parenchymal plaques and CAA (d, h). The lower panel is phosphorylated tau 
staining (monoclonal antibody AT8) in temporal cortical regions of the same patients (i–k); or 
ubiquitin staining for Tg2576 (l). Note that HCHWA-D brains lacks dense-core senile plaque or 
phospho-tau pathology but do show diffuse amyloid plaques (e and i). Flemish APP and PS1 
L282V carriers have phosphorylated tau immunostaining in neurofibrillary tangles, ballooned 
neurites and neuropil threads (j–k). Sections are immunostained with avidin-biotin 
complex/horseradish peroxidase system and color developed with 3’3’diaminobenzidine. Scale bars 
in a–d, 200 μm; and e–l, 20 μm.  
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Table 2. Clinicopathological spectrum for APP mutations within Aβ1-43 coding sequence. 
APP 
Codon*  Substitution 
Position 
within 
Aβ 
Proximity 
to 
secretases 
Nickname Disease  References 
673 AlaÆVal A2V  β-secretase        [43] 
692 AlaÆGly A21G α-secretase Flemish  AD/ Cerebral 
haemorrhage  [31,33] 
693 
GluÆGln E22Q 
merge with 
α-secretase 
Dutch  Cerebral 
haemorrhage  [29,44] 
GluÆLys E22K  Italian  Cerebral 
haemorrhage  [36] 
693 
(merge 
the cell 
with 
above) 
GluÆGly E22G 
also  α-
secretase 
(merge the 
cell with 
above) 
Arctic   AD/ severe CAA 
but no strokes  [38,39] 
 Glu-->Del  E22Δ Japanese  AD; pathology 
unavailable  [45] 
694 AspÆAsn D23N  Iowa    AD/ severe CAA 
but no strokes  [40,41] 
705 LeuÆVal  L34V  -  Severe CAA   [37]  
713 AlaÆThr A42T γ-secretase -  AD/ Cerebral 
haemorrhage  [42]  
714 ThrÆIso T43I 
also  γ-
secretase 
(merge with 
above) 
Austrian AD  [46] 
*Numbered according to the largest APP transcript APP770. 
 
It is clear that APP mutations lying within the Aβ sequence cause pathology by mechanisms distinct 
from those involving the other APP or presenilin (PS) mutations that cause AD. For instance, the AD-
causing mutations in APP or PS were shown to alter APP processing in a manner that increases the 
absolute or relative levels of Aβ42, the more fibrillogenic Aβ species [47]. Consider, for example, APP 
Swedish double mutation (K670N/M671L) that leads to increased absolute levels of Aβ42 along with 
Aβ40 (without changing the Aβ42/Aβ40 ratio), while γ-secretase site APP mutations increase the 
relative levels of Aβ42 by increasing the ratio of Aβ42/Aβ40 [4]. Similarly, PS1 and PS2 mutations 
also increased the relative levels of Aβ42 by increasing the ratio Aβ42/Aβ40 [4]. On the other hand, 
mutations within the Aβ sequence were predicted not only to alter the processing of APP and/or 
increasing total Aβ production, but were also thought to alter the aggregation properties of the 
resulting mutant Aβ peptide. 
Initial studies seemingly supporting this hypothesis, however, were not completely clear. This was 
because the Dutch APP peptide showed highly accelerated fibrillogenic kinetics, increased stability, 
and higher in vitro toxicity; while the kinetics of the Flemish Aβ peptide were even slower than the 
wild-type Aβ and the peptide also did not show any increased toxicity to cells in vitro [48,49,50,51]. 
This obviously contrasted sharply with the clinicopathological consequences as Flemish APP carriers 
had clinical and pathological AD while the Dutch APP patients although had diffuse type of Aβ Int. J. Mol. Sci. 2009, 10  
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deposits, but lacked neuritic, senile plaques characteristic of AD. Subsequent in vitro studies, however, 
showed that compared to wild type and Dutch Aβ, Flemish Aβ was most toxic to differentiated SH-
SY5Y cells in the early stages of aggregation when Aβ fibrils were not observed [51]. In the late stages 
of aggregation, the Dutch peptide remained the most toxic Aβ species, suggesting that Aβ, at least 
under in vitro conditions, is neurotoxic in an initial phase due to its soluble oligomeric or other early 
toxic Aβ intermediate(s), which was distinct from the late neurotoxicity incurred by larger aggregated 
assemblies of Aβ [51,52]. Moreover, it was also suggested that the cytotoxic potential of Aβ lies in 
their ability to form extensive fibrils directly on the cell surface, as preaggregation of Aβ abolished its 
toxic effect on cultured cells [53]. Thus, Dutch Aβ once released from the sites of generation, 
aggregates almost instantaneously in the parenchymal matrix as non-neuritic diffuse plaques [51,54]. 
The Flemish APP, on the other hand, not only leads to increased Aβ production due to an increased 
activity of β-site APP-cleaving enzyme-2 [55], but also slowly fibrillizing mutant Aβ diffuses more 
efficiently to aggregate as one of the largest dense-core amyloid deposits known in AD. Subsequently, 
it was also shown that most of the dense-core amyloid plaques observed in the Flemish APP carriers 
develop in close association with vessel walls [33], perhaps due to entrapment of Aβ in the vascular 
clearance routes [56,57]. Further observations in Flemish APP carriers showed that CAA-related 
plaques could also trigger accumulation of tau-immunoreactive dystrophic neurites in the surrounding 
neuropil similar to dense-core plaques [33] (Figure 2). Vessel association of dense-core plaques might 
not be unique to Flemish APP carriers as suggested by a recent study showing a significant association 
between dense-core plaques and Prussian blue-labelled haeme deposits in sporadic AD and Down’s 
syndrome patients, and even proposing that dense-core plaques are sites of older   
microhaemorrhages [58]. 
Subsequent studies on other APP mutations within the Aβ sequence identified similar or additional 
disease mechanisms. Consider for example, the Italian peptide showing increased propensity to make 
fibrils and peptide-mediated pathogenic effects similar to the Dutch peptide [59,60]. As a matter of 
fact, substitutions at APP 693 codon that cause either a loss of charge (E22Q; Dutch APP) or a change 
of charge (E22K; Italian APP) show increased binding to and degeneration of cerebrovascular smooth 
muscle cells [59] and, not surprisingly, both of them lead to CAA/ haemorrhagic strokes. On the other 
hand, complete deletion of APP 693 codon as in Japanese APP shows altered aggregation property of 
enhanced oligomerization but no fibrillization [45]. This is similar to the Arctic APP variant that also 
increases the propensity of protofibril formation without increasing the rate of fibril formation or the 
production of Aβ [38]. And lastly, the Iowa APP carriers that resemble Flemish and Dutch APP 
carriers show cytotoxicity and aggregation properties that lie between those caused by the Flemish and 
Dutch Aβ peptides [60]. Interestingly, Flemish, Dutch, Italian, Arctic, and Japanese Aβ variants are 
also shown to be more resistant to proteolytic degradation [61,45,62]. Recent data also suggest that 
Dutch, Italian, and Iowa preferably assemble in the presence of GM3 ganglioside [63] while their 
clearance across the blood-brain barrier (BBB) might be reduced as shown for Dutch/Iowa mutant 
[64,65]. It remains to be shown that oligomers of the variant Aβ that are associated with AD changes 
are more synaptotoxic than wild type Aβ oligomers [45]. 
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4. Other Genetic Risk Factors for CAA  
Copy number variations of the APP gene also seem to be important for development of CAA. For 
instance, Down’s syndrome patients who have three copies of APP, have CAA as young as 30 years 
and the severity of CAA increases with age [66]. Down’s syndrome patients are also reported to have 
strokes [67,68,69]. Similarly, duplications of the APP locus in certain French and Dutch families or 
populations demonstrate an autosomal dominant AD and/or lobar cerebral haemorrhage with 
prominent CAA [70,71]. APP duplications increase the absolute amounts of both Aβ42 and Aβ40 
(without changing the ratio), an important factor proposed to lead to Aβ deposition in vessel walls 
[33,72]. Although uncommon, a predominant CAA is also observed in select PS1 mutations like 
Q184D and L282V, amongst others [73,74,75,76,77]. The best studied PS2 mutation, N141I, has also 
been reported to lead to haemorrhagic strokes in Volga-German family [78]. It remains to be shown 
whether some of these mutations, especially those occurring after codon 200 [79], might not alter 
Aβ40 production as has been shown for the majority of PS mutations [80,81]. 
Specific apolipoprotein E (APOE) alleles are not only a strong risk factor for development of AD, 
but are also linked to development of CAA and strokes. CAA related to capillaries and smaller 
arterioles is observed to be closely associated with ApoE-ε4, but not ApoE-ε2 [7]. ApoE-ε4 is also 
independently associated with increased vascular Aβ deposition in large-vessel CAA leading to strokes 
[82,83,84]. On the other hand, ApoE-ε2 appears to promote degenerative changes in the amyloid-laden 
vessel wall and is a cause of stroke independent of Aβ deposition [85,86]. Anecdotal examples of 
individuals homozygous for the APOE-ε4 allele that have a predominant CAA or a CAA-related 
pathology are also described [23]. Lastly, candidate genes involving Aβ degradation pathways have 
also been implicated in the development of CAA [87]. For instance, a polymorphism in the Neprilysin 
gene has been shown to be associated with CAA [88]. For many of these candidate genes, knockout 
mouse models have been made as discussed in the next section. 
5. Mouse Models of Cerebrovascular Amyloidosis 
Most disease models are based on inherited forms of disease that although less common than the 
sporadic forms, are clinically indistinguishable from each other. The first attempts to model the 
archetypal Dutch and Flemish APP cerebral amyloidosis in mice did not show amyloid till at least 18 
months of age [89,90], however, recent experiments have successfully created Dutch APP mice [91]. 
At ≈ 25 months of age, APP Dutch mice demonstrate extensive CAA, smooth muscle cell degeneration 
and haemorrhages – features that are typical of HCHWA-D [91]. Similarly, transgenic mice expressing 
Dutch/Iowa mutant Aβ (Tg-SwDI) at levels below those of endogenous mouse APP have also been 
established that robustly deposit Aβ, particularly in the cerebral microvasculature, from 3 months of 
age [92,93]. However, because mutant Aβ is expected to have altered biophysical properties, any 
direct extrapolation to sporadic CAA has to be made with caution. 
Interestingly, mice overexpressing wild type Aβ such as APP Swedish mice (APP/Sw; e.g., Tg2576 
and APP23 mice), or APP London mice, develop CAA fairly early and have been used as a valid 
model for CAA [94,95,96](www.alzforum.org/res/com/tra). Importantly, APP/Sw mice with unaltered 
relative ratios of Aβ42/Aβ40 are even more representative of sporadic CAA/AD and have been 
employed in several studies. In principle, these mouse models have provided support for many Int. J. Mol. Sci. 2009, 10  
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important concepts in our understanding of cerebral amyloidosis including Aβ deposition in vessel 
walls, as summarized below: 
(1) Mouse models have given a definitive view that Aβ42 is essential for Aβ deposition not only in 
parenchyma but also in vessels. When APP/Sw mice (producing both Aβ40 and Aβ42) are bred 
with mice expressing mutant PS1 (that increases brain Aβ42/Aβ40 ratio), the crossbred mice 
have drastically increased amyloid deposition in parenchyma and vessels compared to single 
transgenic controls [97,98]. These APP/PS1 mice also have a higher number but smaller sizes of 
amyloid deposits most likely due to the extra “seeds” provided by Aβ42 [99]. A similar 
crossbreeding of APP Dutch mice with mice expressing AD-related PS1 G384A mutation also 
increases amyloid depositions and shifts the pathology from vascular to the parenchymal 
compartment [91]. The premise that Aβ42 is essential for Aβ deposition is also neatly answered 
by BRI-Aβ40 and BRI-Aβ42 mice that produce only Aβ40 or Aβ42 [100]. In these mice, a 
fusion construct is utilized wherein the carboxyl terminus sequence of BRI protein, involved in 
amyloid deposition in familial British and Danish dementia, is replaced by a sequence encoding 
either Aβ40 or Aβ42. A proteolytic cleavage of this fusion protein at a furin cleavage site 
immediately preceding Aβ results in high-levels of Aβ40 or Aβ42 secretion. While BRI-Aβ40 
mice expressing high levels of Aβ40 do not develop overt amyloid pathology, the BRI-Aβ42 
mice line expressing lower levels of Aβ42 develop all types of brain amyloid deposits including 
CAA [100]. Crossbreeding of BRI-Aβ42 mice with Tg2576 mice again leads to a massive 
increase in amyloid deposition. These data establish that Aβ42 is essential for amyloid 
deposition in the parenchyma and also in vessels. 
(2) Mouse models have also supported a “protective” role of Aβ40 in plaque deposition and 
therefore in AD pathology, especially when the levels of Aβ40 exceed a critical level. The 
initial data to support a protective role of Aβ40 came from in vitro studies where Aβ40 was 
shown to directly interfere with Aβ42 aggregation by delaying the Aβ42-mediated nucleation 
step at an early stage in the fibrillogenesis process [101]. More recently, γ-secretase site APP 
mutations, like the Austrian (T714I) and French (V715M) mutations, have also been shown to 
cause a drastic decrease in Aβ40 production [102,103]. For instance, Austrian APP reduces 
Aβ40 by ≈ 80% and because Aβ40 is the major physiologically produced peptide (≈ 9 times 
more than Aβ42), a sharp reduction in total Aβ also occurs [102,104]. A similar decrease in 
absolute Aβ40 levels has also been shown for a number of clinical PS mutants [80,81] and 
interestingly, age-of-onset of PS1-linked AD not only correlates inversely with Aβ42 but also 
directly with Aβ40 levels [80,105]. Further studies on mouse models have also provided 
compelling data to support the premise that Aβ40 is anti-amyloidotic. First, results from 
transgenic mice expressing wild-type and various mutant forms of APP suggest that increased 
Aβ40 levels reduce amyloid deposition [106]. Secondly, at least two independent studies 
utilizing knockin PS familial AD mutations crossbred with Tg2576 mice show a greatly 
accelerated plaque pathology accompanied by decreased production of Aβ40 without an 
increase in secreted brain Aβ42 levels [107,108]. Similarly, BRI-Aβ40 mice crossbred with 
either BRI-Aβ42 or Tg2576 mice show greatly reduced brain amyloid deposition compared to 
singly transgenic BRI-Aβ42 or Tg2576 mice [100]. These data all suggest that in the absence of Int. J. Mol. Sci. 2009, 10  
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Aβ42, the clearance of Aβ40 is very high, and depending upon the critical levels of Aβ42, Aβ40 
might even be anti-amyloidotic [72]. 
(3) Recent work on knockout and transgenic mice has provided evidence that Aβ is cleared from 
brain by mechanisms involving microglial uptake, degradation by cellular or extracellular 
proteases, as well as by clearance through vascular route. For instance, in vivo imaging of live 
mice has shown that Aβ is not only taken up by microglia but astrocytes also play a direct role 
in degradation of Aβ [109]. Secondly, knockout mouse models have supported data of Aβ 
degradation by brain proteases such as neprilysin, insulin-degrading enzyme (IDE), endothelin-
converting enzymes-1 and -2, and matrix metalloproteinase-2 and -9 [110]. Consider, for 
example, neprilysin homozygous knockout mice expressing mutant APP and showing an 
expectedly higher burden of brain amyloid including CAA [111]. Thirdly, studies on mouse 
models have demonstrated that Aβ that cannot be locally degraded has the potential to diffuse 
away from the site of production. Non-transgenic brain tissue grafted in APP23 hosts develop 
both diffuse and congophilic amyloid plaques [112]. And finally, experimental studies in mice 
have shown that diffusible Aβ is transported directly across the BBB into the blood, mediated 
by low density lipoprotein receptor-related protein-1 (LRP-1)/ α2-macroglobulin and ApoE 
[113,57]. Mouse models of mutant Aβ have also shown that some of these mutant Aβ such as 
the Dutch/Iowa mutants could be deficient in its clearance across the BBB explaining the robust 
CAA seen in these mutation carriers (Deane et al., 2004; Davis et al., 2006). Studies on rodents 
also support a second vessel-related Aβ clearance route along the periarterial spaces 
[56,113,114]. Exogenous tracer studies in rats show that tracers injected into the parenchyma of 
grey matter in the rat brain drain along perivascular spaces around leptomeningeal arteries to the 
base of the brain, pass through the cribriform plate and, via nasal lymphatics, to deep cervical 
lymph nodes [115]. 
(4) Studies on mouse models have indicated that local production of Aβ by vascular elements is not 
absolutely essential for the development of CAA. This is important as, for instance, hypoxia 
followed by reoxygenation in microvascular smooth vessel cells has been shown to upregulate 
APP and proposed to be an initiating event in the pathogenesis of amyloid angiopathy [116]. 
However, mice that solely produce APP/Aβ from neuronal cells in an endogenous APP 
knockout background drive Aβ pathology in both parenchyma and vessels [114]. Furthermore, 
these studies also lend support to the hypothesis that failure of Aβ vascular drainage and 
entrapment of Aβ in the periarterial space leads to development of CAA [56]. Similarly, 
pathological studies on some of the mouse models have suggested that in certain situations, 
dense plaques in mouse models are also associated with vascular walls as has been proposed 
earlier for sporadic AD [117] and shown for Flemish APP pathology [33]. Recent data from 
Tg2576 and PSAPP mice show that up to 90% of these dense plaques, but not diffuse plaques, 
are centred on vessel walls or reside in the immediate perivascular regions [99]. Similar 
observations have also been made on Tg-SwDI mice where all dense plaques were observed to 
be associated with vessel walls [93]. These data suggest that the mechanisms involved in the 
formation of "neuritic" dense (core) plaques in select AD such as Flemish APP pathology or in 
select transgenic mice such as Tg2576 and PSAPP mice are similar to CAA formation, but 
distinct from those involved in the formation of non-neuritic, diffuse plaques (Figure 3). Int. J. Mol. Sci. 2009, 10  
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Figure 3. Physiological clearance and pathological deposition of Aβ in brain. 
 
(a) The newly synthesized Aβ is locally degraded by glial uptake and cell-associated and 
extracellular proteases or cleared along the periarterial interstitial fluid pathway or directly across 
the BBB through specific receptors or carrier-mediated mechanisms (EC, endothelial cell; SMC, 
smooth muscle cell). (b) At the level of BBB, Aβ is transported into the blood flow via a 
transcytosis mechanism mediated by LRP-1 and P glycoprotein transporters, in association with α2 
macroglobulin and ApoE. A reverse transport from the blood towards the parenchyma is mediated 
by RAGE and LRP-2 receptors in association with apolipoprotein J. In addition, Aβ might be 
sequestered in the blood flow by immunoglobulins, ganglioside GM1, apolipoproteins, soluble 
RAGE receptors and gelsolin. (c) Astrocyte endfeet and pericytes also mediate Aβ intake by 
expressing LRP-1 and -2 receptors. As the production of Aβ exceeds its clearance, Aβ starts to 
deposit. It is possible that in situations of high Aβ42/Aβ40 ratio, highly fibrillogenic Aβ42 deposits 
near the site of production as diffuse plaques. It is also likely that such plaques sequester newly 
synthesized Aβ and mature to dense plaques. However, in situations where Aβ42/Aβ40 ratio 
remains unaltered or low, the major Aβ gradient is set towards vessels where Aβ42 seeds the 
deposition of more abundantly produced, and more diffusible, Aβ40 to form vessel-related CAA 
and dense plaques. Figure is not drawn to scale (adapted from Pirici et al., with permission from the 
publisher [118]. 
 
(5) Mouse models demonstrate that similar to large vessel-CAA in humans [119], amyloid 
associated with vessel walls is predominantly of the Aβ40 type. A similar biochemical profile is 
also observed for the compact dense-core plaques, which is in contrast to diffuse plaques that Int. J. Mol. Sci. 2009, 10  
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are predominantly composed of Aβ42 [120]. Conversely, situations that lead to a drastic 
reduction of Aβ40 also drastically reduce the prevalence of CAA and dense-core plaques as 
observed in Austrian APP pathology [102]. Tg2576 and PSAPP mouse models preferentially 
producing Aβ40 also deposit Aβ40-enriched cerebrovascular amyloid [121,99]. Dutch APP 
mice also deposit more mutant Aβ40 than mutant Aβ42 in vessels [91]. Furthermore, 
experimental work on rodents has demonstrated that Aβ40 is more prone to compact as dense 
deposits in contrast to the faster aggregating Aβ42 that preferentially deposits as diffuse 
plaques. When soluble Aβ40 and Aβ42 are injected in rat brain, soluble Aβ40 forms 
congophilic, fibrillar dense deposits while Aβ1-42 forms only diffuse deposits [122]. Lastly, 
BRI-Aβ42 mice that solely secrete Aβ42 also have Aβ42 peptide trafficked and deposited in 
vessels [100]. Thus, mouse models support the viewpoint that although "Aβ40" plays an 
important role in development of vessel-associated compact plaques, most likely due to a more 
efficient vascular clearance and its high abundance, Aβ42 on its own also has the potential to 
migrate and deposit in association with vessels; and without a critical relative level of Aβ42, 
Aβ40 clearance is too efficient to allow deposition. 
(6) Mouse models have partly elucidated the role of ApoE which is otherwise poorly understood. 
ApoE has been shown to bind to Aβ [123], and studies on transgenic mice suggest that ApoE, 
especially ApoE-ε4, has a role in Aβ fibrillization [124]. When APP London mice are crossbred 
with ApoE knockout mice, Aβ chiefly deposits as diffuse, nonfibrillar plaques. However, when 
these mice were crossbred with mice transgenically expressing human ApoE-ε4, they develop 
far more fibrillogenic, dense-core plaques and CAA than when crossbred with mice expressing 
the ApoE-ε3 isoform [124]. Because dense-core plaques and CAA are rich in Aβ40, these data 
suggest that ApoE-ε4 has a role in Aβ40 fibrillization as also suggested by studies on AD [125]. 
(7) Transgenic mouse models serve as a useful model to study CAA-associated pathological 
changes. Vascular Aβ deposits in mouse models are shown to cause degeneration of vascular 
smooth muscle cells and of other vascular components typically identified in AD and hereditary 
cerebral amyloidosis [126,91,11]. Some mouse models also show ultrastructural microvascular 
abnormalities in non-amyloidotic vessels such as endothelial cell loss, basement membrane 
thickening, and degeneration of smooth muscle cells and pericytes as shown for AD [99,11]. 
Additionally, mouse models have shown that basement membrane abnormalities could also 
contribute to development of CAA as capillary basement membrane thickening precedes the 
development of CAA in TGF-β transgenic mice [127]. And lastly, transgenic mouse models 
such as APP23 and Tg2576 have shown that vascular amyloidosis is indeed the cause of 
spontaneous haemorrhages as both cerebral microhaemorrhages and fatal lobar haemorrhages 
occur in these mice [126,99]. 
(8) Finally, mouse models of amyloidosis have proved to be essential in testing therapeutic amyloid 
targeting from vessels. A number of active and passive immunotherapeutic approaches such as 
peripheral sequestering utilizing non-immune mechanisms have been successfully tried in these 
mouse models [128,129,130,131,132]. In an active immunization trial on an AD mouse model, 
behavioural and cognitive abnormalities were shown to be reversed coinciding with ≈ 50% 
reduction in dense-core plaques [129]. Similarly, a passive immunization approach in Tg2576 
mouse model has been shown to revert some of the BBB abnormalities observed in these mice Int. J. Mol. Sci. 2009, 10  
 
 
1884
[133]. Furthermore, mouse models also reproduce some of the side effects of anti-Aβ 
vaccinations. For instance, similar to one of the encephalitic patients from the Aβ active 
immunization trial revealing presence of multiple cortical haemorrhages in association with T-
cell inflammatory infiltrates [134], APP23 mice receiving passive anti-Aβ immunization were 
also shown to have infrequent but severe CAA-associated microhaemorrhages [135]. 
Furthermore, similar to breakdown of BBB seen in Tg2576 [99], autopsy of one of the 
encephalitic patients from the active immunization trial revealed that antibody titers in 
cerebrospinal fluid equalled those in plasma, again indicating a severe breakdown of the BBB 
[136]. These data indicate that mouse models of amyloidosis could be instrumental in 
understanding some of the ill effects of anti-amyloid drug targeting. However, data from mouse 
models should always be viewed with caution as mouse models also have serious limitations as 
reviewed recently [72]. As an example, vaccination trials targeting Aβ N-terminus in humanized 
mouse models could easily miss the adverse effects caused by sequestration of physiological Aβ 
because human and murine Aβ have a different N-terminus. Despite these limitations, mouse 
models would continue to provide important clues in the understanding of the processes 
involved in vascular amyloidosis and in causing dementia. 
6. Conclusions 
In this review, I have discussed how molecular pathology of hereditary cerebrovascular amyloidosis 
due to APP mutations within the Aβ domain, as well as experimental studies in transgenic mouse 
models have helped to partially dissect molecular mechanisms involved in Aβ cerebrovascular 
amyloidosis. Firstly, the mutant forms of Aβ causing AD/cerebral haemorrhage were discussed that 
strongly support the role of APP in the disease mechanism and provide one of the strongest rationales 
for studies of factors that influence abnormal metabolism and aggregation of Aβ in the causation of 
CAA with or without AD. Secondly, studies on hereditary cerebrovascular amyloidosis and mouse 
models were discussed that suggest that while an absolute or relative increase in Aβ42 or an increased 
Aβ42/Aβ40 ratio is important for parenchymal plaque deposition and development of an AD 
phenotype, increased Aβ with an unaltered Aβ42/Aβ40 ratio favours cerebrovascular amyloidosis. 
However, critical relative levels of Aβ42 are also important as without this, the clearance of Aβ is too 
efficient to allow deposition. Thirdly, these data suggest that a low fibrillogenic potential of Aβ could 
also favour plaque compaction as is the case with Flemish Aβ that leads to the formation of large, 
neuritic, dense-core plaques. And lastly, by illuminating the relationships between specific lesions 
such as CAA and dense-core plaques and their molecular components, studies on hereditary 
cerebrovascular amyloidosis and mouse models have shown that CAA and dense-core plaques could 
be a spectrum of the same disease mechanism. Thus, molecular pathological studies of cerebrovascular 
amyloidosis and relevant mouse models would continue to provide detailed insights into the 
pathogenesis of CAA and contribute to the development of targeted therapeutic strategies. 
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